Aim announces milestone in covid-19 treatment and prevention efforts with first patient dosed in study evaluating ampligen as part of combination treatment for patients with cancer and covid-19

Ocala, fla., nov. 25, 2020 (globe newswire) -- aim immunotech inc. (nyse american: aim) today announced developments in its work to develop new treatments or preventive strategies for covid-19, the disease caused by sars-cov-2.

AIM Ratings Summary

AIM Quant Ranking